Today: 20 May 2026
Browse Category

NASDAQ:ROIV 11 December 2025 - 20 May 2026

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences shares surged 22% to $25.82 Friday after the company reported positive Phase 2 data for brepocitinib in cutaneous sarcoidosis and filed for U.S. approval in dermatomyositis. Trading volume exceeded 24 million shares. Roivant posted a quarterly loss of $313.7 million on $2 million in revenue, with $4.5 billion in cash and equivalents.
8 February 2026
·
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
7 February 2026
··
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences shares climbed near $21.50 on December 11, approaching 52-week highs after the company’s Investor Day outlined plans for at least three product launches and four regulatory filings by 2028. The stock has gained about 85% over six months, pushing market value to roughly $15 billion. Management advanced timelines for key drug programs, including brepocitinib and IMVT-1402.
11 December 2025

Stock Market Today

  • Applied Digital, Viasat, CECO Environmental, and HNI Shares Plunge Amid Rising Yields and Oil Prices
    May 20, 2026, 5:35 PM EDT. Applied Digital (APLD), Viasat, CECO Environmental, and HNI stocks suffered sharp declines in afternoon trading due to surging 10-year Treasury yields hitting 4.56%, a one-year high, and rising WTI crude oil prices near $104 per barrel amid geopolitical tensions. The market also reacted negatively to the lack of concrete agreements from the recent U.S.-China summit. Applied Digital remains notable, trading near its 52-week high at $42.53 after signing long-term AI data center deals expected to generate $7 billion in revenue over 15 years, reflecting strong positioning in the growing AI infrastructure sector. The broader sell-off weighed on major indexes, including the S&P 500 and Nasdaq, pulling them back from record highs.

Latest articles

MicroAlgo Stock Jumped 40%—The Quantum Release Behind MLGO’s Sudden Move

MicroAlgo Stock Jumped 40%—The Quantum Release Behind MLGO’s Sudden Move

20 May 2026
New York, May 20, 2026, 17:09 EDT MicroAlgo Inc. shares jumped 39.95% on Wednesday after the Shenzhen-based algorithm company said it had proposed a quantum image edge-extraction algorithm for noisy images, drawing heavy trading in a small-cap stock already prone to sharp moves. MLGO closed at $5.36, after touching $6.87 intraday, and slipped to $5.22 in after-hours trading, meaning trades after the regular closing bell. (Google) The move mattered because the rally was not tied to an earnings release or a signed contract. It was a market reaction to a technical announcement: MicroAlgo said the new method combines quantum computing
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
FuelCell Energy surges as AI-fueled rally hits again, analysts wary

FuelCell Energy surges as AI-fueled rally hits again, analysts wary

20 May 2026
FuelCell Energy shares surged 16.5% to $20.22 Wednesday, rebounding after a two-day selloff. The move tracked a 1.5% gain in the Nasdaq Composite and renewed interest in companies supplying power to AI data centers. FuelCell reported a $26.1 million quarterly loss and a declining backlog, despite higher revenue and new data-center proposals. Peers traded mixed, with Bloom Energy up and Plug Power down.
Go toTop